Functionality of retinal vessels in central serous retinopathy: A comparison between eplerenone and photodynamic therapy

Purpose To investigate retinal vessels functionality in patients with acute central serous chorioretinopathy (CSC) undergoing oral eplerenone or photodynamic therapy (PDT) using Retinal Vessel Analyzer (RVA) and Dynamic Vessel Analyzer (DVA), respectively. Methods Treatment naïve acute CSC patients presenting between May 2017 and June 2017 were recruited. A complete ophthalmological examination was performed in all participants before and after oral eplerenone (eplerenone group) or half-dose PDT (PDT group). Results Eighteen eyes of 18 patients affected by acute CSC underwent either oral eplerenone (10 eyes of 10 patients, 47.6 ± 8.9 years old) or half-dose PDT (8 eyes of 8 patients, 57.4 ± 6.2 years old), respectively. After 2 months of treatment, non-significant variations of static retinal vessels analysis, dynamic arterial and venous dilatation were reported in eplerenone group. Similarly, in PDT group non-significant variations of static retinal vessels analysis, dynamic arterial and venous dilatation were found after 2 months of treatment. Conclusions Static and dynamic retinal functionalities in acute CSC may not be significantly improved by oral eplerenone and half-dose PDT. Although their choroidal effects, these treatments could not exert a significant effect on retinal vessels motility. Thus, both local and systemic therapies might not help avoiding the onset of vascular and other retinal known alterations of CSC.

[1]  O. Meijer,et al.  Choroidal arteriovenous anastomoses: a hypothesis for the pathogenesis of central serous chorioretinopathy and other pachychoroid disease spectrum abnormalities , 2022, Acta ophthalmologica.

[2]  M. Falcão,et al.  Foveal and Extrafoveal Effects of Half-Dose Photodynamic Therapy in Chronic Central Serous Chorioretinopathy: A Cohort Study , 2021, Seminars in ophthalmology.

[3]  M. Varano,et al.  Photodynamic Therapy with Verteporfin for Chronic Central Serous Chorioretinopathy: A Review of Data and Efficacy , 2020, Pharmaceuticals.

[4]  H. Arifoğlu,et al.  Evaluation of retinal vessel diameters in eyes with active central serous chorioretinopathy. , 2020, Retina.

[5]  R. Spaide Choroidal Blood Flow: Review and Potential Explanation for the Choroidal Venous Anatomy Including the Vortex Vein System. , 2020, Retina.

[6]  M. Parravano,et al.  OCTA characterisation of microvascular retinal alterations in patients with central serous chorioretinopathy , 2020, British Journal of Ophthalmology.

[7]  Min Zhao,et al.  Mineralocorticoid antagonists in the treatment of central serous chorioetinopathy: Review of the pre-clinical and clinical evidence. , 2019, Experimental eye research.

[8]  G. Querques,et al.  Multimodal Imaging Assessment of Vascular and Neurodegenerative Retinal Alterations in Type 1 Diabetic Patients without Fundoscopic Signs of Diabetic Retinopathy , 2019, Journal of clinical medicine.

[9]  M. Parravano,et al.  Optical Coherence Tomography Parameters as Predictors of Treatment Response to Eplerenone in Central Serous Chorioretinopathy , 2019, Journal of clinical medicine.

[10]  G. Querques,et al.  Early response to the treatment of choroidal neovascularization complicating central serous chorioretinopathy: a OCT-angiography study , 2019, Eye.

[11]  L. Leocani,et al.  Functional and morphological changes of the retinal vessels in Alzheimer’s disease and mild cognitive impairment , 2019, Scientific Reports.

[12]  M. Parravano,et al.  Eplerenone Versus Observation in the Treatment of Acute Central Serous Chorioretinopathy: A Retrospective Controlled Study , 2018, Ophthalmology and Therapy.

[13]  G. Querques,et al.  Response of central serous chorioretinopathy evaluated by multimodal retinal imaging , 2018, Eye.

[14]  G. Querques,et al.  Retinal vessels functionality in eyes with central serous chorioretinopathy , 2017, British Journal of Ophthalmology.

[15]  M. Abràmoff,et al.  DYSFUNCTIONAL AUTONOMIC REGULATION OF THE CHOROID IN CENTRAL SEROUS CHORIORETINOPATHY , 2017, Retina.

[16]  E. Souied,et al.  Assessment of choroidal topographic changes by swept source optical coherence tomography after photodynamic therapy for central serous chorioretinopathy. , 2014, American journal of ophthalmology.

[17]  J. Jonas,et al.  Choroidal vessel diameter in central serous chorioretinopathy , 2013, Acta ophthalmologica.

[18]  Min Zhao,et al.  MINERALOCORTICOID RECEPTOR ANTAGONISM IN THE TREATMENT OF CHRONIC CENTRAL SEROUS CHORIORETINOPATHY: A Pilot Study , 2013, Retina.

[19]  Jason Noble,et al.  Central serous chorioretinopathy: update on pathophysiology and treatment. , 2013, Survey of ophthalmology.

[20]  K. Nishida,et al.  CHOROIDAL THICKNESS IN CENTRAL SEROUS CHORIORETINOPATHY , 2013, Retina.

[21]  Min Zhao,et al.  Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy. , 2012, The Journal of clinical investigation.

[22]  L. Yannuzzi,et al.  Peripheral Retinal Detachments and Retinal Pigment Epithelial Atrophic Tracts Secondary to Central Serous Pigment Epitheliopathy , 2012, Ophthalmology.

[23]  K. Park,et al.  COMPARISON OF EFFICACY AND SAFETY BETWEEN HALF-FLUENCE AND FULL-FLUENCE PHOTODYNAMIC THERAPY FOR CHRONIC CENTRAL SEROUS CHORIORETINOPATHY , 2011, Retina.

[24]  Leopold Schmetterer,et al.  Use of the retinal vessel analyzer in ocular blood flow research , 2010, Acta ophthalmologica.

[25]  Ritu Gadia,et al.  Sympathetic-parasympathetic activity and reactivity in central serous chorioretinopathy: a case-control study. , 2006, Investigative ophthalmology & visual science.

[26]  T. Lai,et al.  Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin: a novel treatment at the primary disease level , 2003, The British journal of ophthalmology.

[27]  L. Yannuzzi,et al.  Corticosteroids and central serous chorioretinopathy. , 2002, Ophthalmology.

[28]  J. Slakter,et al.  Systemic findings associated with central serous chorioretinopathy. , 1999, American journal of ophthalmology.

[29]  A. Ho,et al.  Digital indocyanine green videoangiography of central serous chorioretinopathy , 1994 .

[30]  A. Laties,et al.  Peptidergic innervation of the retinal vasculature and optic nerve head. , 1990, Investigative ophthalmology & visual science.

[31]  J. Pulido,et al.  The incidence of central serous chorioretinopathy in Olmsted County, Minnesota, 1980-2002. , 2008, Ophthalmology.

[32]  J. Slakter,et al.  INDOCYANINE GREEN VIDEOANGIOGRAPHY OF OLDER PATIENTS WITH CENTRAL SEROUS CHORIORETINOPATHY , 1996, Retina.

[33]  J. Flammer,et al.  Choroidal capillary and venous congestion in central serous chorioretinopathy. , 1996, American journal of ophthalmology.

[34]  M. Tamai,et al.  Increased and decreased choroidal blood flow elicited by cervical sympathetic nerve stimulation in the cat. , 1995, The Japanese journal of physiology.

[35]  O. Lund,et al.  Fluorescein and indocyanine green angiographies of central serous choroidopathy by scanning laser ophthalmoscopy. , 1993, American journal of ophthalmology.

[36]  Demichelis,et al.  Evaluation of the , 1992, Physical review. B, Condensed matter.